DTx East Agenda
DTx East is going virtual. Working with industry leaders, we are providing even more high-quality learning and networking opportunities than usual, but this time, through a truly interactive virtual experience.
Through a more personalized and flexible experience, attendees will be able to participate in live polls, actively or passively take part in roundtables, instantly message fellow attendees, join a variety of networking sessions and much more. Oh, and not to mention the rockstar speaker faculty and crucial topics on the agenda.
With the recent changes in healthcare, it is now more crucial than ever to accelerate digital therapeutics into the hands of patients with unmet medical needs.
Conference Day 1: Workshops
The digital therapeutics industry is being tried and tested both in the clinic and real world, reporting some outstanding results for patients. However, there are only a few examples of commercial success demonstrated in space. This workshop will deep-dive into the various commercial opportunities, how to approach them and how to identify the best partner for you.
- Workshop 1 - The Business of Digital Therapeutics
- Workshop 2 - The Regulatory Masterclass
Workshop Leaders:
Chris Wasden, Head of HappifyDTx, Happify Health
Mette Dyhrberg, Founder & Chief Executive Officer, Mymee
Pablo Pantaleoni, Vice President & General Manager of Health, Headspace
Presentation: An Inside Look at the Business of Digital Therapeutics
- A brief overview of the various business models adopted by digital therapeutic companies
- Where can we see commercial success in the industry so far?
- When should digital therapeutics companies begin searching for reimbursement opportunities and who can offer them these opportunities?
Breakout Discussions
Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry. Make notes on the virtual platform for all members of the group to contribute to, on the following:
- What are the current business models being used within the industry and which are demonstrating the most success?
- How do some business models favour certain types of digital therapeutic over others?
- How can we learn from others successes and failures to ensure we are moving forward as an industry?
- Can pharma help provide effective and recurring reimbursement for digital therapeutics?
- What can we learn from other areas of digital health?
Networking Break
Feedback Session
Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised, via interactive polls, during this collaborative discussion.
Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:
- A deeper understanding of the various business models demonstrated by digital therapeutic companies
- Up-to-date information on business models of varying successes in the current industry
- A clear understanding of current routes to market and their intricacies
- Robust knowledge on how the current commercial landscape impacts your work in this space
- Your questions answered by industry leaders and your peers
End of Workshop 1
Workshop Leaders:
Scott Kellogg, Senior Vice President, Regulatory Affairs, Quality Assurance, GMP & Clinical Operations, Akili Interactive
Austin Speier, Chief Strategy Officer, Click Therapeutics
Presentation: An Introduction to DTx Regulation
- A look at the different levels of regulatory approval available for digital therapeutics
- Who can the digital therapeutics industry work with to begin and obtain regulatory approval?
- How can digital therapeutics companies best work with regulators for mutual success?
Breakout Discussions
Splitting into smaller groups, you will discuss the intricacies of the regulatory process for digital therapeutics. Make notes on the virtual platform for all members of the group to contribute to, on the following:
- What are the different levels of regulatory approval for DTx and how are they defined?
- How can we best work with the FDA to speed up the regulatory process and ensure both entities are on the same page?
- How can we learn from others’ successes and failures to ensure we are moving forward as an industry?
- What impact is the FDA Pre-Cert program having on digital therapeutics?
- Where should digital therapeutics be focusing clinically for FDA regulatory approval?
Networking Break
Feedback Session
Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members, via interactive polls, will be raised during this collaborative discussion.
Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:
- A clear understanding of how digital therapeutics can obtain regulatory approval
- What claims you can make for each level of regulation
- An understanding of current FDA clinical trial guidelines in the space
- What regulators want and need to see from digital therapeutics for successful regulatory approval
- Your questions answered by industry-leading experts and your peers
End of Workshop 2
Throughout Main Conference
- All Day Networking
- On-Demand Content
Networking Available All Day
-
9:00am – 6:00pm: Day 2, Thursday, September 17th
-
9:00am – 1:00pm: Day 3, Friday, September 18th
As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.
Here is how you will be able to achieve this, outside of the networking sessions on the agenda:
- See who’s in the room – you will be able to message all live attendees and connect with those who respond.
- Schedule 1-2-1 video calls with your connections at any time that suits you.
- Open Networking – think of this as the event lobby where you can replicate those all-important “water-cooler” moments.
You will be able to hop seamlessly between networking and on-going agenda sessions at any point.
On-Demand Content Available All Day
-
9:00am – 6:00pm: Day 2, Thursday, September 17th
-
9:00am – 1:00pm: Day 3, Friday, September 18th
DTx East is bursting at the seams with interactive, live content but there are also pre-recorded sessions from more industry-leaders that you can view at your leisure.
These recordings will be available throughout the day, ensuring that you don’t miss any sessions that you want to view or take part in that are happening in real-time.
The Potential of Digital Therapeutics for Treatment in the Real World
- S-Alpha therapeutics is trying to discover real world area, can be managed by digital therapeutics
- An example of development of digital therapeutics which has been discovered according to real world area
- Insight to reach out to the market with digital therapeutics in the real world
Seung Eun Choi, Chief Executive Officer, S-Alpha Therapeutics
Conference Day 2
- Thursday September 17th
Conference Platform Opens
The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.
Location: Stage
Chairs Opening Remarks
Matthew Tucker, Executive Director, Strategy & Transformation, Highmark Health
Presentation: Innovative Partnerships, Driving Patient Outcomes and Value
- Why does digital/pharma/device partnerships make sense?
- Share with the audience vision/mission behind our partnership – Why working together is best for patients
- What were the opportunities/challenges we faced while scaling this partnership?
- What does success look like, what are the long term goals for this partnership?
Chris Lento, Head, Healthcare Partnerships, Noom
Jennifer Hartman, Director of Business Development, Life Sciences Partnerships, Noom
Wellness Break
Get-up and have a stretch before the next session begins.
Panel Discussion & Interactive Q&A: Digital Therapeutics in the Covid-19-Impacted Healthcare System
In just a few months, huge disruption has occurred to healthcare systems across the world as a result of Covid-19. Digital therapeutics are uniquely positioned to deliver for patients with unmet medical needs where more traditional methods may now not be fit for purpose. Hear from industry leaders on how their organizations have adapted to new opportunities. Hear the experts’ thoughts on:
- How has Covid-19 changed our belief in what digital therapeutics can do for patients?
- What opportunities have opened up due to the recent changes in healthcare systems?
- How have payers adapted their thoughts on digital therapeutics in this new age?
- How can we better work with patients to ensure their new behaviours are factored into our products?
- What more can we do as an industry to ensure digital therapeutics fill the gaps in healthcare where non-digital methods have previously fallen short?
David Klein, Chief Executive Officer, Click Therapeutics
Liz Kwo, Medical Director, Digital Health, Anthem
Eddie Martucci, Chief Executive Officer, Akili Interactive
Chuck Gammal, Partner, Simon Kucher & Partners
Peter Hames, Chief Executive Officer, Big Health
10:05am
Optional Break
Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.
10:05am
Open Q&A with Speakers
This is your chance to pose your burning questions to the expert speakers from the previous panel.
Actively or passively take part in this session.
David Klein, Chief Executive Officer, Click Therapeutics
Liz Kwo, Medical Director, Digital Health, Anthem
Eddie Martucci, Chief Executive Officer, Akili Interactive
Representative from Simon Kucher & Partners
Peter Hames, Chief Executive Officer, Big Health
Location: Networking Area
Speed Networking
In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event.
This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.
Your future collaborators or partners could be just one click away!
DTx East Virtual will now split into two tracks.
Personalize your experience by hopping in and out of sessions and meetings seamlessly, view on-demand content, or spend time in the Networking area.
11:05am
Presentation: Determining, demonstrating and communicating the value of digital therapeutics programs using real world data
- What are common real world data sources utilized by the life sciences industry today, and how are they used to measure the value of digital therapeutics programs?
- Review study designs that may be used to demonstrate and communicate digital therapeutic program effectiveness
Rena Meadows, Associate Principal, Real World Solutions, IQVIA
Mitch DeKoven, Senior Principal – Health Economics/Outcomes Research, Real World Insights, IQVIA
11:30am
Wellness Break
Get-up and have a stretch before the next session begins.
11:35am
Presentation: The Patient Perspective in Digital Therapeutics
- What do patients really think of digital therapeutics?
- An insight into the process of a patient using digital therapeutics over traditional drugs
- Where can digital therapeutics improve to improve patient engagement, effectiveness and experience?
Burt Rosen, Former President, Society for Participatory Medicine
Jen Horonjeff, Founder & Chief Executive Officer, Savvy Cooperative
12:00pm
Wellness Break
Get-up and have a stretch before the next session begins.
Location – Sessions
12:05pm
Panel Discussion: Going Digital? – Digital Therapeutic Clinical Trials
- What are the benefits of virtual clinical trials for digital therapeutics over traditional trials?
- Are the results we’ve seen from virtual clinical trials as good and robust as traditional trials?
- What do payers think of this new and novel approach for clinical data?
- What are the drawbacks of virtual clinical trials compared with traditional trials?
- How do regulators view virtual clinical trials for digital therapeutics?
Malinda Peeples, Senior Vice President, Clinical Services, Programs & Research, Welldoc
Derek Richards, Chief Scientific Officer, SilverCloud Health
Shaheen Lakhan, Head, Clinical / Neurology & Pain Management Consultant, Fern Health / Cambridge Health Alliance
Kate Rosenbluth, Founder & Chief Scientific Officer, Cala Health
Brian Johnson, Director, Applied Innovation, Otsuka Pharmaceuticals
12:35pm-2:00pm
Lunch
Finally, a lunch at a conference that is completely your choice!
Use this extended break to have your regular lunch, spend time with your family and give your brain a break. Recharge for the afternoon session.
11:05am
Interactive Roundtable: Unravelling Digital Therapeutics Regulation – What it Means for You
- A discussion on what evidence is required for FDA approval and what payers and clinicians want to see
- What has been the impact of the FDA Pre-Cert program on digital therapeutics?
- Understanding where best to prioritise clinical efforts in relation to regulatory approval
Actively or passively take part in this discussion.
Marisa Cruz, Chief Medical Officer, Limbix
Acacia Parks, Chief Science Officer, Happify Health
Ravi Nunna, Medical Advisor, CureApp
11:45am
Wellness Break
Get-up and have a stretch before the next session begins.
11:50am
Interactive Roundtable: Pharma-DTx Partnerships
- What have we learnt from the recent partnership break-ups?
- How have Pharma’s views on digital therapeutics changed over the last few months?
- Do digital therapeutics companies need to present their value differently compared to pre-Covid-19?
Actively or passively take part in this discussion.
Melinda Decker, Chief Commercial Officer, Mymee
Amir Lahav, Executive Director, Head of Digital Medicine, Karyopharm Therapeutics
12:25pm
Wellness Break
Get-up and have a stretch before the next session begins.
12:35pm-12:55pm
Open Q&A with Speakers
Actively or passively take part in this discussion.
Malinda Peeples, Senior Vice President, Clinical Services, Programs & Research, Welldoc
Derek Richards, Chief Scientific Officer, SilverCloud Health
Shaheen Lakhan, Vice President, Head of R&D / Neurology & Pain Management Consultant, The Learning Corp / Cambridge Health Alliance
Kate Rosenbluth, Founder & Chief Scientific Officer, Cala Health
Brian Johnson, Director, Applied Innovation, Otsuka Pharmaceuticals
Day 2 of DTx East includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.
Location: Expo Area
Tour of Expo
Take a tour of the virtual Expo and interact with partners of DTx East to understand more about their services.
2:20pm
Presentation: Offering Combined Therapies: Digital Health & Over-The-Counter (OTC) Medicines
- A case study looking at how 2Morrow partnered with GSK to offer a combined behavioral and pharmaceutical treatment for nicotine addiction
- Lessons learned from 3 years of real-world experience offering digital behavioral therapy combined with over the counter (OTC) Nicotine Replacement Therapy to address nicotine addiction via employer wellness and population health channels
Jo Masterson, Chief Executive Officer, 2Morrow Inc
James Karl, National Account Manager, GSK
2:45pm
Wellness Break
Get-up and have a stretch before the next session begins.
2:50pm
Presentation: Optimizing Patient Engagement In Digital Therapeutic Trials by Leveraging Digital Solutions and a Virtual Research Team
- Collaborate with patient representative for software configuration and user testing
- Assist patients along their treatment journey with patient-centric software and communication tools
- Closely monitor data in real-time to gain actionable insights into the patient experience
Adam Samson, Director of Clinical Operations, Curebase
3:15pm
Wellness Break
Get-up and have a stretch before the next session begins.
3:20pm
Panel Discussion: Building a Healthcare Ecosystem for Digital Therapeutics Adoption
- How are clinicians and healthcare providers viewing digital therapeutics?
- How should digital therapeutic companies work together to build the infrastructure that will get these products to patients?
- What are the key questions that providers have when digital therapeutic companies approach them?
- What does the ideal infrastructure for getting digital therapeutics to patients look like?
- Should digital therapeutic companies be exploring a “digital pharmacy”-type system?
Gregory Dodell, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease, The Mount Sinai Hospital
Patty Scalzo, Director, Diabetes Technology Initiatives, The Association of Diabetes Care & Education Specialists (ADCES)
Audrey Kern, Global Medical Director, Pear Therapeutics
Joe Perekupka, Chief Commercial Officer, Palo Alto Health Sciences
3:50pm
Optional Break
Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.
2:20pm
Interactive Roundtable: Digital Therapeutics & Telehealth
- How has healthcare delivery changed over the past few months?
- How have the recent changes opened up more opportunities for digital therapeutics?
- How should digital therapeutics companies work with telehealth providers to get these products into the hands of more patients in need?
Actively or passively take part in this discussion.
John Stamatopoulos, SVP, Payor Strategies, Happify Health
3:00pm
Wellness Break
Get-up and have a stretch before the next session begins.
3:05pm
Interactive Roundtable: Patient-centric Development for Patient Engagement, Adherence and Clinical Outcomes
- How can we best design digital therapeutics to keep patients engaged from the start?
- When do conversations with patients need to start in the development process?
- How can we marry the worlds of real-world research and product development?
Actively or passively take part in this discussion.
Davina Pallone, Vice President, Product, Fruit Street
Chris Wasden, Head of HappifyDTx, Happify Health
Jessica Lipschitz, Associate Director, Digital Behavioural Health & Informatics Research Program, Brigham & Women’s Hospital
Madhavi Jagdish, Former Director, Product Design, Pear Therapeutics
3:45pm
Wellness Break
Get-up and have a stretch before the next session begins.
3:50pm
Open Q&A with Speakers
This is your chance to pose your burning questions to the expert speakers from the previous panel.
Actively or passively take part in this session.
Gregory Dodell, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease, The Mount Sinai Hospital
Patty Scalzo, Director, Diabetes Technology Initiatives, The Association of Diabetes Care & Education Specialists (ADCES)
Audrey Kern, Global Medical Director, Pear Therapeutics
Joe Perekupka, Chief Commercial Officer, Palo Alto Health Sciences
Location: Stage
Wellness Break
Get-up and have a stretch before the next session begins.
Presentation: Using Real-World Data to Decode “What Works” in Digital Care Delivery
Andy Blackwell, Chief Scientific Officer, Ieso Digital Health
Wellness Break
Get-up and have a stretch before the next session begins.
Presentation: Specialty Pharmacy? Why do I Need One for my Prescription DTx?
- What is a specialty pharmacy, what is a hub, and why is it needed?
- How would the mechanics of a specialty pharmacy work in DTx vs for a drug?
- How can I utilize a specialty pharmacy for my prescription DTx?
Ed Cox, Executive Vice President, Strategic Alliances & Global Head of Digital Medicine, EVERSANA
Tom Doyle, Sr Vice President, Global Strategic Accounts, EVERSANA
Brian Davis, Vice President Strategy and Innovation, EVERSANA
Wellness Break
Get-up and have a stretch before the next session begins.
Panel Discussion & Interactive Q&A: What is the True Value of Digital Therapeutics?
- Where does the true “value” of digital therapeutics lie?
- How does this value change based on the new Covid-19-impacted healthcare systems we find ourselves in?
- With a huge increase in the demote for remote digital care, how does this impact the value of digital therapeutics?
- Does this open up new reimbursement opportunities outside of the ones we have been previously exploring?
- Will DTx/Drug combination therapies open up more commercialization and reimbursement opportunities for the industry?
Jonas Thinggaard, Head of Technology Scouting and Incubation, Digital Therapeutics, Novo Nordisk
Ofer Leidner, Co-Founder & President, Happify Health
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Megan Coder, Executive Director, Digital Therapeutics Alliance
5:45pm – 7:30pm
Virtual Drinks
Share a virtual drink with old friends or new connections. At small virtual tables, this is your chance to casually interact with the rest of the Digital Therapeutics industry.
5:45pm – 6:05pm
Open Q&A with Speakers
This is your chance to pose your burning questions to the expert speakers from the previous panel.
Actively or passively take part in this session.
Jonas Thinggaard, Head of Technology Scouting and Incubation, Digital Therapeutics, Novo Nordisk
Ofer Leidner, Co-Founder & President, Happify Health
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Megan Coder, Executive Director, Digital Therapeutics Alliance
Conference Day 3
- Friday September 18th
Conference Platform Opens
The conference platform opens an hour before the sessions begin so that you can plug the presentations, panels and discussions into your calendar for the day ahead.
Location: Stage
Chairs Opening Remarks
Sarah Jackson, Chief of Staff, Click Therapeutics
Panel Discussion: How Should Digital Therapeutics be Impacting the Lives of Patients?
Digital therapeutics have a huge opportunity to deliver for patients with unmet medical needs in a wide range of health conditions, particularly in the Covid-19-impacted healthcare systems we find ourselves in. However, crucial questions must be asked to ensure that these products truly deliver for patients. Hear the experts’ thoughts on:
- As we stand today, what are digital therapeutics doing for patients?
- In what areas can digital go above and beyond traditional therapeutics?
- What is going to stop digital therapeutics from reaching their full potential?
- What areas of success in the wider digital health landscape can we learn from when attempting to demonstrate the value of digital therapeutics?
- How can we work closer with patients to ensure further adoption of digital therapeutics?
Joanna Mitri, Staff Physician / Instructor in Medicine, Joslin Diabetes Center / Harvard Medical School
Anand Iyer, Chief Strategy Officer, Welldoc
Ted James, Chief, Breast Surgical Oncology & Director, Breast Care Center, Beth Israel Deaconess Medical Center
Mae-ellen Gavin, Senior Vice President, Product, Akili Interactive
Rochelle Porper, Vice President, Business Development, Palo Alto Health Sciences
Lindsey Miller, Development Associate, The Accelerated Cure Project for MS
9:35am
Optional Break
Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.
9:35am
Open Q&A with Speakers
This is your chance to pose your burning questions to the expert speakers from the previous panel.
Actively or passively take part in this session.
Joanna Mitri, Staff Physician / Instructor in Medicine, Joslin Diabetes Center / Harvard Medical School
Anand Iyer, Chief Strategy Officer, Welldoc
Ted James, Chief, Breast Surgical Oncology & Director, Breast Care Center, Beth Israel Deaconess Medical Center
Mae-ellen Gavin, Senior Vice President, Product, Akili Interactive
Rochelle Porper, Vice President, Business Development, Palo Alto Health Sciences
Lindsey Miller, Development Associate, The Accelerated Cure Project for MS
Location: Stage
Wellness Break
Get-up and have a stretch before the next session begins.
Panel Discussion & Interactive Q&A: What do Pharma Really Think of Digital Therapeutics?
Answering the age-old question to truly identify what pharma thinks of digital therapeutics. In recent months, there has been a smattering of both partnerships and breakups between pharma and DTx companies. This panel, stacked with pharma leaders, will deep-dive into the pharmaceutical perspective of digital therapeutics. Hear the experts’ thoughts on:
- From a pharma perspective, what is the true value of digital therapeutics?
- How has the impact of Covid-19 changed your view on the potential of digital therapeutics?
- What have we learned from both the more and less successful pharma partnerships?
- Does there need to be a new approach taken to ensure successful partnerships in the future?
- How can both DTx companies and pharma companies ensure successful and mutually beneficial partnerships?
Michael Latauska, Director, Digital Health, Boehringer Ingelheim
Lauren Li, Head of Digital Health, Ipsen
Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis
Paul Upham, Head, Smart Devices, Roche / Genentech
Rachel Sha, Vice President, Digital Business Development, Sanofi
10:30am
Speed Networking
Through the purpose built Networking on function, get ready to expand your network through randomly assigned 1 on 1 quick fire interactions. You can choose who you want to “connect” and then set-up 1-2-1 in-depth meetings throughout the rest of the event.
This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.
Your future collaborators or partners could be just one click away!
10:30am – 10:50am
Open Q&A with Speakers
This is your chance to pose your burning questions to the expert speakers from the previous panel.
Actively or passively take part in this session.
Michael Latauska, Director, Digital Health, Boehringer Ingelheim
Lauren Li, Head of Digital Health, Ipsen
Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis
Paul Upham, Head, Smart Devices, Roche / Genentech
Rachel Sha, Vice President, Digital Business Development, Sanofi
Optional Break
Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.
11:15am
Presentation: An Insight into European Digital Therapeutics Regulation and an Update on the new German Legislation
- A deep-dive into the process of obtaining DTx reimbursement through the new German legislation
- How has this changed DTx reimbursement opportunities in Germany?
- How are GAIA’s digital therapeutics moving through this new reimbursement pathway?
Matthias Zenker, Partner, GAIA AG
11:30am
Wellness Break
11:35am
Presentation: Improving Behavioral Health through Virtual Reality Digital Therapeutics
- Why VR is such an appealing medium for behavioral health interventions
- How COVID-19 has accelerated the coupling of digital therapeutics and telehealth
- A look at BehaVR’s products, pipeline and results so far
Aaron Gani, Founder & Chief Executive Officer, BehaVR
11:50am
Wellness Break
11:55am
Presentation: Becoming a Virtual Sleep Disorder Provider
- How is Dreem enabling access to sleep in a similar way to a healthcare provider
- Showcase of real world evidence on Dreem’s insomnia therapy studies
- Discussion will focus on the personalization of digital therapeutics
Vik Panda, Managing Director, North America, Dreem
11:15am
Interactive Open Mic Session
This open mic session will enable you to suggest the topics you would like to hear more about.
If there was a topic that was covered in the agenda but you wish to go deeper, or a new topic that wasn’t showcased, this is your chance to discuss with peers. The choice is yours!
Facilitators will initiate the discussion and ensure that topics are stuck to and will cultivate guidance and answers to your questions.
Actively or passively take part in this discussion.
Owen McCarthy, Co-Founder & President, MedRhythms
Andy Molnar, Vice President, Market Access, Cognoa
Location: Stage
Wellness Break
Get-up and have a stretch before the next session begins.
Panel Discussion: A Minds Eye View of Digital Therapeutics – An Investor Perspective
As the digital therapeutics enters the next phase in its lifecycle, the sentiment from the investor community is changing. Tap into the mind of leading investors to understand how digital therapeutic companies and their partners should alter their approaches. Hear the experts’ thoughts on:
- What are investors looking for from digital therapeutic companies to prompt them to pull the trigger on investment?
- How has Covid-19 impacted our assessment of the investment opportunities in digital therapeutics?
- How can DTx companies prepare to secure multiple rounds of funding from the start?
- Where do investors think the risk lies in investing in digital therapeutics?
- How can DTx best source the right investment partner to ensure future success?
Chihiro Hosoya, Head of Venture Management & Business Development, Rx+ Business Accelerator, Astellas Pharma
Debbie Lin, Executive Director, Boehringer Ingelheim Venture Fund
Zack Lynch, Managing Partner, JAZZ Venture Partners
Caleb Winder, Managing Director, MemorialCare Innovation Fund
Brent Vaughan, Healthcare Venture Capital, Morningside Ventures
Location: Sessions
Open Q&A with Speakers
This is your chance to pose your burning questions to the expert speakers from the previous panel.
Actively or passively take part in this session.
Chihiro Hosoya, Head of Venture Management & Business Development, Rx+ Business Accelerator, Astellas Pharma
Debbie Lin, Executive Director, Boehringer Ingelheim Venture Fund
Zack Lynch, Managing Partner, JAZZ Venture Partners
Caleb Winder, Managing Director, MemorialCare Innovation Fund
Brent Vaughan, Healthcare Venture Capital, Morningside Ventures